Potassium News and Research

RSS

Regular consumption of pistachios lowers risk of CHD: Study

A new nut and blood lipid study published on May 10, 2010, in Archives of Internal Medicine, led by Dr. Joan Sabate and colleagues at Loma Linda University (Loma Linda, Calif.), confirms that eating nuts, like pistachios, have a total and LDL (bad)-cholesterol-lowering effect, supporting the evidence that regular nut consumption can lower the risk of coronary heart disease.

18 May 2010

Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients

Sanofi-aventis announced today the initiation of a multinational, randomized double-blind Phase IIIb trial, PALLAS, to assess the potential clinical benefit of Multaq(R) (dronedarone) in over 10, 000 patients with permanent atrial fibrillation (AF) to reduce major adverse cardiovascular events. The announcement was made during Heart Rhythm 2010, the Heart Rhythm Society's 31st Annual Scientific Sessions.

12 May 2010

Merck reports non-GAAP EPS of $0.83 for first-quarter 2010

Merck & Co., Inc. today announced financial results for the first quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the first quarter of $0.83, which excludes purchase accounting adjustments, merger-related expenses and restructuring costs, as well as a tax charge related to the recently enacted health care reform legislation. First-quarter GAAP EPS was $0.09.

4 May 2010

Acorda Therapeutics reports AMPYRA gross sales of $3.4 million for first-quarter 2010

Acorda Therapeutics, Inc. today announced its financial results for the first quarter of 2010.

30 Apr 2010

Salix Pharmaceuticals receives FDA complete response letter for GIAZO Tablets NDA

Salix Pharmaceuticals, Ltd. today announced the Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for GIAZO™ (balsalazide disodium) Tablets 1.1 g. for the treatment of mild-to-moderate active ulcerative colitis in patients 18 years and older.

29 Apr 2010

Update on ICA-105665 clinical development plans for treatment of epilepsy and pain

Icagen, Inc. today provided an update on clinical development plans for ICA-105665, the Company's novel drug candidate for the treatment of epilepsy and pain.

28 Apr 2010

Salix Pharmaceuticals announces novel patient and health care provider support program for HE

Salix Pharmaceuticals, Ltd. today announced plans for the Hepatic Encephalopathy Living Program (H.E.L.P.). H.E.L.P. is a first-of-its-kind patient and health care provider support program for the management of hepatic encephalopathy (HE) and will launch on May 24, 2010. The program will provide patients with HE educational materials, co-pay assistance, treatment adherence support and a 24-hour toll-free hotline.

27 Apr 2010

Two new studies highlight benefits of drinking 100% fruit juice

Consumption of 100 percent fruit juice is closely linked to improved nutrient intake and overall diet quality in children and teens, according to new research presented yesterday at the Experimental Biology 2010 meeting.

27 Apr 2010

Temperature-sensing ability in proteins remain a mystery

Scientists at The Scripps Research Institute and the Genomics Institute of the Novartis Research Foundation (GNF) have shed new light on the molecular mechanism that enables us to sense temperature, such as the heat from a sizzling stove. In addition to contributing to our knowledge of basic biology, the findings could one day lead to new therapies for conditions such as acute or chronic inflammatory pain.

24 Apr 2010

CAPS launches new service for admixture and delivery of Hibernation Therapeutics' Adenocaine microplegia

Central Admixture Pharmacy Services, Inc. (CAPS®), a B. Braun company, announced today the launch of its newest service for the admixture and delivery of Hibernation Therapeutics' patented Adenocaine™ microplegia, the world's first low-potassium, non-depolarizing cardioplegia solution.

From B. Braun Melsungen AG 23 Apr 2010

Mandatory cuts for salt content in processed foods on the horizon

This Tuesday The Institute of Medicine (IOM) has urged the US Food and Drug Administration to start regulating the amount of salt in processed foods. This measure according to them can do what years of advising people to cut down on salt have failed to do.

22 Apr 2010

DDW2010 Investor Event to provide update on TARGET 1 and TARGET 2 Phase 3 trials

Salix Pharmaceuticals, Ltd. today announced that the Company will host a DDW2010 Investor Event on Monday, May 3 2010 from 9:00 p.m. to 10:00 p.m. Central Time (10:00 p.m. to 11:00 p.m. ET).

22 Apr 2010

Icagen to present study results of ICA-105665 at Tenth Eilat Conference on New Antiepileptic Drugs

Icagen, Inc. today announced that results from a study of ICA-105665 in patients with photosensitive epilepsy will be presented at the Tenth Eilat Conference on New Antiepileptic Drugs on Tuesday, April 27, 2010 in Eilat, Israel. The presentation will be made by Dorothee Kasteleijn-Nolst Trenite, MD, University Medical Centre Utrecht and Universita di Roma Sapienza II, Rome, Italy.

21 Apr 2010

Nutrition experts call for sodium reduction strategies

Responding to the health threat posed by Americans' over-consumption of sodium, experts in the department of nutrition at Harvard School of Public Health (HSPH) and The Culinary Institute of America (CIA) called today for sodium reduction strategies that are strong and effective-and that maximize the enjoyment people derive from food.

21 Apr 2010

More testimony on Patel trial

In the ongoing trial of Dr. Jayant Patel for manslaughter of three men and grievous injury to the fourth during his tenure as Director of surgery at Bundaberg base hospital new testimony has surfaced. Patel had pleaded not guilty.

21 Apr 2010

Acorda Therapeutics to initiate Phase 1 clinical trial of GGF2 for heart failure in mid-2010

Acorda Therapeutics, Inc. today announced plans to initiate a Phase 1 single-dose clinical trial of the Company's compound, Glial Growth Factor 2 (GGF2), in patients with heart failure in mid-2010, based on an IND filed with the U.S. Food and Drug Administration (FDA) on March 19, 2010. GGF2 has been shown to protect heart muscle and restore cardiac function in preclinical models of heart failure, myocardial infarction and cardiotoxicity.

20 Apr 2010

Patel trial testimony by anesthetist: bleeding and kidney damage may have led to early death

In the Jayant Patel manslaughter case new testimony has surfaced. Dr. Patel has been accused of causing the deaths of three Queensland patients and permanently injuring another when he performed operations as director of surgery at the Bundaberg Base Hospital between 2003 and 2005. He had pleaded not guilty.

20 Apr 2010

Combivent Inhalation Aerosol's "essential use" status effective through 2013

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that the U.S. Food and Drug Administration (FDA) has determined that the "essential use" status of Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol will be effective through December 31, 2013. With this ruling, COMBIVENT will remain on the market and available to the more than two million chronic obstructive pulmonary disease (COPD) patients who rely on it as a bronchodilator.

15 Apr 2010

Clinical trial data on AMPYRA Extended Release Tablets to be presented at AAN Annual meeting

Acorda Therapeutics, Inc. today announced that four new analyses of clinical trial data on AMPYRA™ (dalfampridine) Extended Release Tablets 10 mg are being presented at the 62nd American Academy of Neurology Annual meeting.

13 Apr 2010

FDA approves Mylan Pharmaceuticals' ANDA for generic Hyzaar

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Losartan Potassium and Hydrochlorothiazide (HCTZ) Tablets 100 mg/12.5 mg, the generic version of Merck and Co., Inc.'s antihypertensive Hyzaar®.

12 Apr 2010

Potassium News and Research

Regular consumption of pistachios lowers risk of CHD: Study

Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients

Merck reports non-GAAP EPS of $0.83 for first-quarter 2010

Acorda Therapeutics reports AMPYRA gross sales of $3.4 million for first-quarter 2010

Salix Pharmaceuticals receives FDA complete response letter for GIAZO Tablets NDA

Update on ICA-105665 clinical development plans for treatment of epilepsy and pain

Salix Pharmaceuticals announces novel patient and health care provider support program for HE

Two new studies highlight benefits of drinking 100% fruit juice

Temperature-sensing ability in proteins remain a mystery

CAPS launches new service for admixture and delivery of Hibernation Therapeutics' Adenocaine microplegia

Mandatory cuts for salt content in processed foods on the horizon

DDW2010 Investor Event to provide update on TARGET 1 and TARGET 2 Phase 3 trials

Icagen to present study results of ICA-105665 at Tenth Eilat Conference on New Antiepileptic Drugs

Nutrition experts call for sodium reduction strategies

More testimony on Patel trial

Acorda Therapeutics to initiate Phase 1 clinical trial of GGF2 for heart failure in mid-2010

Patel trial testimony by anesthetist: bleeding and kidney damage may have led to early death

Combivent Inhalation Aerosol's "essential use" status effective through 2013

Clinical trial data on AMPYRA Extended Release Tablets to be presented at AAN Annual meeting

FDA approves Mylan Pharmaceuticals' ANDA for generic Hyzaar

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Single-cell proteomics: Revealing proteome diversity from cellular heterogeneity to non-canonical biology

Latest News